<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03444506</url>
  </required_header>
  <id_info>
    <org_study_id>GPL/CT/2013/001/II</org_study_id>
    <nct_id>NCT03444506</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR)</brief_title>
  <acronym>GSP 301- PoC</acronym>
  <official_title>A Single-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group, Comparative Environmental Exposure Chamber (EEC) Study to Evaluate Efficacy, Safety and Tolerability of Two Fixed Dose Combination (FDC) Products of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray as Compared to the FDC of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray, Olopatadine Nasal Spray, and Placebo in Patients With Seasonal Allergic Rhinitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glenmark Pharmaceuticals Ltd. India</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glenmark Pharmaceuticals Ltd. India</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single-center, double-blind, placebo-controlled study of FDC olopatadine hydrochloride and
      mometasone furoate nasal spray (Molo; also referred as GSP 301) was conducted in subjects
      with seasonal allergic rhinitis. In this study, the efficacy and safety of two regimens (BID
      and QD) of the FDC (i.e. Molo 1 and Molo 2) were evaluated compared to placebo nasal spray,
      DYMISTA® and PATANASE®.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 27, 2014</start_date>
  <completion_date type="Actual">February 28, 2014</completion_date>
  <primary_completion_date type="Actual">February 28, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean post-treatment instantaneous Total Nasal Symptoms Score (iTNSS) for Molo 1 and Molo 2 compared with placebo from baseline to end of treatment</measure>
    <time_frame>15 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean post-treatment iTNSS for Molo 1 and Molo 2 compared with reference products Dymista and Patanase</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean post-treatment iTNSS for reference products Dymista and Patanase compared with placebo</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of action assessed by comparing change in iTNSS after the first dose</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in post-treatment instantaneous Total Symptoms Score (iTSS) (Molo 1 and Molo 2 versus Active Comparator)</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in individual instantaneous Nasal Symptoms Scores (iNSS) (Molo 1 and Molo 2 versus Active Comparator)</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in instantaneous Total Ocular Symptom Score (iTOSS) (Molo 1 and Molo 2 versus Active Comparator)</measure>
    <time_frame>15 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean post-treatment Environmental Exposure Chamber - Rhinoconjunctivitis Quality-of-Life Questionnaire (EEC-QoLQ) scores</measure>
    <time_frame>15 days</time_frame>
    <description>Score from 0 (better outcome) - 6 (worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responses to a reflective Global Assessment of Tolerability and Acceptance Questionnaire (GATAQ)</measure>
    <time_frame>15 days</time_frame>
    <description>Scale of 0 (very much acceptable) - 6 (not acceptable)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Placebo nasal spray</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo nasal spray - 2 sprays per nostril, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Molo 1 (also referred as GSP 301-2 NS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed Dose Combination of Molo nasal spray (olopatadine hydrochloride 665 mcg and mometasone furoate 25 mcg nasal spray) - 2 sprays per nostril, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Molo 2 (also referred as GSP 301-1 NS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed Dose Combination of Molo nasal spray (olopatadine hydrochloride 665 mcg and mometasone furoate 50 mcg nasal spray) - 2 sprays per nostril, QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DYMISTA nasal spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fixed Dose Combination of azelastine hydrochloride 137 mcg and fluticasone propionate 50 mcg nasal spray - 1 spray per nostril, BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PATANASE nasal spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Olopatadine hydrochloride 665 mcg nasal spray - 2 sprays per nostril, BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Molo 1 (also referred as GSP 301-2 NS)</intervention_name>
    <arm_group_label>Molo 1 (also referred as GSP 301-2 NS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Molo 2 (also referred as GSP 301-1 NS)</intervention_name>
    <arm_group_label>Molo 2 (also referred as GSP 301-1 NS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo nasal spray</intervention_name>
    <arm_group_label>Placebo nasal spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DYMISTA nasal spray</intervention_name>
    <arm_group_label>DYMISTA nasal spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PATANASE nasal spray</intervention_name>
    <arm_group_label>PATANASE nasal spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients aged 18 to 65 years (inclusive) with a clinical history of
             seasonal allergic rhinitis (SAR) (for at least 2 years) and exhibiting a positive skin
             prick test

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Patients with known hypersensitivity to any of the components of the formulation

          -  Patients with a history of seasonal asthma during ragweed season.

          -  Patient requiring chronic use of inhaled or systemic corticosteroids

          -  Patients with perennial rhinitis; non-allergic rhinitis; or ocular infection within 3
             weeks before the screening

          -  Patients with history of acute or significant chronic sinusitis or chronic purulent
             post-nasal drip or Rhinitis Medicamentosa as determined by the Investigator.

          -  Patients with history of narrow-angle glaucoma, increased intraocular pressure,
             posterior subcapsular cataract, urinary retention, uncontrolled hypertension, severe
             Coronary Artery Disease, Ischemic Heart Disease, uncontrolled Diabetes Mellitus,
             Hyperthyroidism, Renal Impairment or Prostatic Hypertrophy, and those receiving MAO
             inhibitor therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sudeesh Tantry, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Glenmark Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glenmark Investigational Site 1</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L4W 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2018</study_first_submitted>
  <study_first_submitted_qc>February 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2018</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SAR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Mometasone Furoate</mesh_term>
    <mesh_term>Olopatadine Hydrochloride</mesh_term>
    <mesh_term>Azelastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

